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Vagus nerve stimulation (VNS) is a neuromodulation therapy
increasingly used for treating drug‐resistant epilepsy. However, it
remains to be determined which patients are best suited for the
treatment, and it is difficult to predict the therapeutic effect before the
implantation. Mutations in some genes could lead to epilepsy. Here we
report two cases of pediatric patients with drug‐resistant epilepsy
treated by VNS therapy: Patient 1 with ARX mutation achieved good
outcomes; Patient 2 with the CDKL5 mutation did not show
improvement. Additionally, the therapeutic impact of VNS on brain
networks was investigated, hoping to provide some empirical evidence
for a better understanding of the mechanism of VNS treatment.

© The authors 2020. This article
is published with open access at
http://jnr.tsinghuajournals.com
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Introduction

In 1997, vagus nerve stimulation (VNS) was
approved by the US Food and Drug
Administration (FDA) for use in treating
drug‐resistant epilepsy. Since then until 2018,
VNS devices have been implanted in over 80,000
patients worldwide [1]. Genetic factors play a
crucial role in the pathogenesis of epilepsy. In
the few monogenic forms of symptomatic

epilepsy, X‐linked cyclin‐dependent kinase‐like
5 (CDKL5) and aristaless‐related homeobox
(ARX) genes were found to be responsible for
X‐linked epileptic encephalopathies associated
with early‐onset seizures and drug‐resistant
myoclonic epilepsy [2]. Studies on using VNS
therapy in treating gene‐related epilepsy are
limited. In this paper, two cases were reported: a
4.2‐year‐old girl with an ARX mutation who
experienced a good reduction in seizure frequency
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and a 3.3‐year‐old girl with a CDKL5 mutation
who showed no reduction in seizure frequency
following the initiation of VNS therapy.

magnetic resonance imaging (MRI) at the ages
of 6 months, 2 years, and 4 years did not reveal
remarkable

findings.

Hypsarrhythmia

and

epileptic spasms were detected by the initial

2

Case report

electroencephalogram (EEG). One month before
initiating VNS therapy, the interictal EEG

2.1

General information

showed generalized polyspikes and waves in

Patient 1 was a 4.2‐year‐old girl, the younger
child of fraternal twins, born by C‐section at 37
weeks of gestation with a birth weight of 2.3 kg.
During pregnancy, she was physically healthy
with no history of hypoxic‐ischemic encephalo‐
pathy

at

birth.

She

was

born

to

non‐

consanguineous parents with no family history
of epilepsy or neuropsychiatric disorders. At the
age of 6 months, an unprovoked nodding spasm
began to occur in clusters, and from then on, her
psychomotor development was delayed. Brain

Fig. 1

the background (Fig. 1) and generalized spikes
activities during sleep, while ictal EEG detected
generalized fast activities in cluster, synchronized
with each nodding. A de novo mutation in the
ARX gene (c.1151G>A, p.R384H) was spotted by
genetic testing. Moreover, Sanger sequencing of
the ARX gene was negative for her fraternal
twin sister. At the time of seizure onset, the
patient was diagnosed with epileptic spasms,
evolving gradually to Lennox‐Gastaut syndrome
at 2.5 years old.

Interictal EEG of Patient 1 and Patient 2 before and after VNS therapy. (A) and (B) EEG of Patient 1 showed

generalized polyspikes and waves before VNS and 6 months after VNS. (C) and (D) EEG of Patient 2 showed generalized
polyspikes and waves before VNS and 6 months after VNS.
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Patient 2 was a 3.3‐year‐old girl, born at 40
weeks and 2 days of gestation. Her mother had
gestational diabetes. Before her birth, the fetal
heart rate declined to 100 beats per minute
(bpm), which resulted in an emergency
C‐section. She was born to non‐consanguineous
parents with no family history of epilepsy.
Seizures’ onset occurred on day 18 after birth;
subsequently, her psychomotor development
was delayed. Brain MRI was performed five
times from the onset of seizures to the time of
starting VNS therapy, showing unremarkable
results. The initial EEG recorded hypsarrhythmia
and epileptic spasms, while repeated EEG at the
time of VNS detected the occurrence of interictal
generalized polyspikes and waves (Fig. 1). Three
types of seizures were recorded in this case,
including epileptic spasms, focal seizures, and
myoclonic seizures. A missense mutation in the
CDKL5 gene (c.134A>T, p.L45M) was spotted
by gene testing. She was diagnosed with
West syndrome and did not respond well to
Table 1

the antiepileptic drugs used before starting
VNS therapy. The demographic and clinical
characteristics of the two patients are listed in
Table 1.
2.2

Vagus nerve stimulation therapy

From December 2017 to August 2018, the two
patients took part in a multicenter, double‐blind
clinical trial for assessing the safety and
effectiveness of VNS for children with
intractable epilepsy, where they received
surgeries for VNS system implantation (G112,
Beijing PINS Medical Co., Ltd., Beijing, China).
The follow‐up period was 26 weeks [3]; after the
VNS system implantation procedure, the
patients were followed up at 8, 14, 20, and 26
weeks. Initial stimulation was performed two
weeks postoperatively with the following
conditions: a current output of 0.5 mA,
frequency of 30 Hz, the pulse width of 500 μs,
30 s of signal‐on time, and 5 min of signal‐off
time. During the 26‐week follow‐up period, only

Demographics and clinical characteristics of the two patients.
Case

Patient 1

Patient 2

Gender

Female

Female

Age at start of the study

4.2 years

3.3 years

Age at onset of seizures

6 months

18 days

Variant site

ARX (c.1151G>A, p.R384H)

CDKL5 (c.134A>T, p.L45M)

Variant type

de novo; missense

de novo; missense

Seizure type

Focal seizure; spasm seizures;

Focal seizure; spasm seizures;

tonic seizures

myoclonus seizures

MRI

Normal

Normal

EEG

Hypsarrhythmia  generalized polyspikes

Hypsarrhythmia  generalized polyspikes

and waves

and waves

Epileptic syndrome

West syndrome  Lennox Gastaut syndrome

West syndrome  Lennox Gastaut syndrome

Therapy history

VPA; ACTH; LEV; OXC; TPM; VGB; CLB; KD

VPA; LEV; ACTH; OXC; LTG; TPM; CLB; KD

Seizures frequency at baseline

90/month

90/month

Seizures frequency at 6‐month 18/month
follow‐up

95/month

Reduction in seizures

−5%

78%

VPA: sodium valproate; ACTH: adrenocorticotropic hormone; LEV: levetiracetam; OXC: oxcarbazepine; TPM: topamax; VGB:
vigabatrin; CLB: clobazam; KD: ketogenic diet; LTG: lamotrigine.
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the stimulus current magnitude was adjusted,
while the other parameters remained unchanged.
Patients’ diaries were utilized to assess the
efficacy of VNS treatment. Routine EEG
registrations were recorded before implantation
and at 26‐week follow‐up. The Ethics
Committee of the Shenzhen Children’ s Hospital
approved the data collection and analysis.
2.3

Brain network analyses

Quantitative EEG (qEEG) analysis was conducted.
EEG blocks from eyes‐open resting state were
quantitatively
analyzed
using
MATLAB
toolboxes: EEGLAB [4] and ENA (http://www.
neuro.uestc.edu.cn/name/shopwap/do/index/co
ntent/319). The EEG data processing steps are
shown in Fig. 2. The properties of the brain
network, such as clustering coefficient (C), local
efficiency (Le), characteristic path length (L),
and global efficiency (Ge), were evaluated
before the surgery and at 26‐week follow‐up
based on coherence and phase‐locking value
(PLV) within δ (1–4 Hz), θ (4–8 Hz), α (8–14 Hz),
β (14–30 Hz), and β1 (14–20 Hz) bands.

3

Results

The changes in seizure frequency and current
output are displayed in Fig. 3. In the case of

Fig. 2

Patient 1, after 14 weeks, the stimulation current
output was elevated to 1.8 mA, and seizure
frequency was markedly reduced from about
three times per day to less than once a day. In
the case of Patient 2, when the current output
reached 1.5 mA for the first time, the seizure
frequency decreased by approximately 30%;
however, it gradually increased when the
current output was set to 1.8 mA. Even after the
current was set back to 1.5 mA at 20‐week
follow‐up, the seizures’ frequency still continued
to increase. After six months of VNS therapy,
seizures’ frequency of Patient 1 decreased by
78% compared to the baseline, while Patient 2
experienced no improvement (Table 1). Table 2
listed the VNS parameters at 26‐week follow‐up.
Regarding the visual examination, in the two
patients, there was no significant change in the
overall impression of the EEG. Additionally,
qEEG analysis was carried out. Figure 4
illustrated the changes in the characteristics of
the brain network. Compared with baseline,
both patients’ brain networks demonstrated the
same trend in the β and β1 bands, such as an
increase in clustering coefficient, an increase in
local efficiency, a decrease in characteristic path
length, and an increase in global efficiency,
indicating that, after VNS treatment, the brain
network’s global parallel information processing
and transmission capacity might become stronger.

EEG data processing process. REST, technique standardization electrode reference [5, 6].
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Fig. 3 The seizure frequency of Patient 1 and Patient 2
over time. Red circles mean that the VNS setting is
adjusted at this point, and the adjustments of current
output are displayed in the red dotted box beside the circle.
The stimulating current for Patient 1 was increased to
1.5 mA two weeks after the startup of the VNS system,
remained unchanged until 14‐week follow‐up, and
increased to 1.8 mA at 14‐week follow‐up. The stimulating
current for Patient 2 was increased to 1.5 mA two weeks
after startup, remained unchanged until 14‐week follow‐up,
and then increased to 1.8 mA. Due to the gradual increase
in seizures frequency, the stimulating current was
decreased back to 1.5 mA at 20‐week follow‐up.
Table 2 Stimulator parameters in two cases at 26th‐week
follow‐up.
Parameters

Patient 1

Patient 2

Output current (mA)

1.8

1.5

Signal frequency (Hz)

30

30

Pulse width (μs)

500

500

Signal on time (s)

30

30

Signal off time (s)

300

300

Magnet output current (mA)

2.0

1.7

Magnet pulse width (μs)

500

200

Magnet signal on time (s)

30

30

4

Discussion

Two cases with drug‐resistant epilepsy caused
by different genetic mutations were reported.
Both were treated with VNS therapy, yet had
different outcomes. After six months of VNS
treatment, Patient 1 demonstrated a reduction in
seizures’ frequency by 78% compared to the
baseline, while Patient 2’s condition did not

improve. We followed up with the patients
through phone calls after 26 weeks. At 15‐month
follow‐up by telephone interviews, Patient 1
was seizure‐free, while Patient 2’s state
remained unchanged. From the end of the
26‐week follow‐up period until the telephone
interview, the stimulation parameters and
medications were not adjusted for both patients
owing to personal reasons. The poor outcomes
in Patient 2’s case could be attributed to a failure
in adjusting the suitable parameters for her
condition. Nevertheless, this may indicate that if
the patient did not respond to a specific setting
in the short term, the stimulation would not
work and their condition will remain the same
as time passes. Improving the patients’
compliance when adjusting the parameters of
VNS should be considered; for example,
establishing a remote parameter adjustment
platform could allow patients to adjust settings
at home.
Physicians must find the correlation between
drug‐resistant epilepsy associated with genetic
mutations and the efficacy of VNS therapy as it
is important when assessing and choosing the
suitable treatment for their patients. In the
literature, reports about the efficacy of VNS in
reducing seizures in patients with drug‐resistant
epilepsy due to gene mutations are limited
[7–11]. Most of these researchers examined the
relationship between CDKL5 and neuronal
voltage‐gated sodium‐channel alpha‐subunit
(SCN1A) genes and epilepsy. Stephen et al. [7]
conducted a retrospective review of 20 pediatric
patients with malignant mutations in SCN1A
who underwent VNS treatment for drug‐
resistant epilepsy. At 6‐month follow‐up, 9
patients showed improvement with > 50%
reduction in generalized tonic‐clonic seizures; 4
patients reported improvement in cognitive or
speech development; 7 patients who had their
Journal of Neurorestoratology
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Fig. 4 Changes in brain network properties. (A) and (B) Brain network properties pre‐ and post‐operation (26‐week
follow‐up) based on coherence and PLV of Patient 1. (C) and (D) Brain network properties pre‐ and post‐operation (26‐week
follow‐up) based on coherence and PLV of Patient 2. The y‐coordinate is the unitless value of brain network properties. PLV,
phase locking time; C, clustering coefficient; Le, local efficiency; L, characteristic path length; Ge, global efficiency.

VNS implanted at other institutions reported
subjective benefit, with 4 indicating “marked
improvement” or seizure freedom. The efficacy
of VNS in patients with CDKL5 gene mutations
was examined previously [11]. Lim et al.
surveyed 222 patients: only 17.1% were treated
with VNS therapy and more than two‐thirds of
the patients showed improvement in seizure
control with VNS, but none of them became
seizure‐free [11]. In a retrospective multicentered
study, 347 children with predominantly
generalized seizures caused by genetic and
structural epilepsy, such as Dravet syndrome or
Lennox‐Gastaut syndrome, received VNS
treatment and reported favorable outcomes, but
the improvement was marginally lower
compared to the entire population [12].
Unfortunately, Patient 2 did not show any
improvement regarding seizure control with
VNS therapy.
ARX mutations are more common in men

than in women. Phenotypic polymorphism
associated with X‐linked dominant ARX
mutations has been well documented; however,
heterozygous female carriers were not thoroughly
studied [13]. ARX is crucial for the interneurons’
development in deep gray matter, cerebral
cortex, and hippocampus [14, 15]. Patient 1
presented with West syndrome and infantile
epileptic encephalopathy; such phenotypes are
consistent with the mutations in the ARX gene,
usually resulting in drug‐resistant epilepsy and
unfavorable outcomes. To the best of our
knowledge, this is the first case report about a
female patient (Patient 1) with ARX mutation
treated by VNS.
Mutations in ARX and CDKL5 genes can
result in various brain disorders, further leading
to significant differences in brain networks. EEG
could reveal the therapeutic efficacy of VNS.
Baba et al. [8] reported one case of an 8‐year‐old
girl with a CDKL5 mutation who underwent

Journal of Neurorestoratology

144

VNS therapy for two years. After two years of
VNS therapy, her seizure frequency was
markedly reduced, there is an improvement in
EEG background slowing, paroxysmal high‐
voltage slow waves disappeared, and abnormal
electrical activities strikingly decreased. From
the conventional point of view, in our study,
there was no significant change in the overall
impression of the EEG in the two patients,
which could be attributed to the short duration
of VNS treatment (only six months). However,
by comparing brain networks’ properties before
and after the VNS operation, the qEEG revealed
that the global parallel information processing
and transmission capacity in both patients’ brain
networks were relatively stronger after
six‐month VNS treatment, potentially proving
the efficacy of the therapy.
Epilepsy is now increasingly considered as a
disorder of brain network connectivity [16].
Studying if VNS therapy can induce the
reorganization of a functional brain network is
vital. In the last few years, the correlation
between clinical improvement generated by
VNS therapy and topological changes in brain
networks was explored [16–22]. In the study by
Fraschini et al., the EEG recordings of ten
patients with drug‐resistant epilepsy were
analyzed and the functional connections
between EEG signal channels were estimated
using the phase lag index (PLI) [19]. The
findings showed that, as a result of VNS therapy,
functional brain networks were reorganized and
rearranged to a more effective (i.e., more
integrated) network structure, and these
VNS‐induced alterations were associated with
the observed clinical improvements. Wang et al.
constructed brain networks from EEG signals of
20 pediatric patients with Dravet syndrome by
comparing the recordings before treatment and
after 6 months, 12 months, and 24 months of
VNS therapy [22]. They noticed that, in α and β

bands, after 6 months of VNS therapy,
characteristic path length decreased, global
efficiency increased, and transitivity increased
in both responders and nonresponders. Our
findings revealed that the brain network’s
functional efficiency was enhanced compared
with baseline in both patients (even though
Patient 2 is a nonresponder); this is consistent
with Wang et al.’s results in β band, but no
significant change was observed in α band. It
was shown previously that VNS can have acute
or chronic effects on the EEG rhythms of adult
patients with drug‐resistant epilepsy, mainly, in
δ band [17], θ band [19, 21], α band [21], or γ
band [16, 18]. However, in the study of pediatric
patients, after VNS therapy, the EEG networks
in α and β bands were changed significantly,
indicating the essential difference between the
adult and pediatric patients’ brain networks or
between patients with different etiologies.
Brain network analyses of these two patients
will provide empirical evidence for future
studies. For a better understanding of the
efficacy and mechanism of VNS therapy, we
recommend that, in the future, brain network
analysis is added to the clinical investigation of
each patient receiving VNS treatment, which
could offer help when managing challenging
gene mutation‐related epilepsy cases.

5

Conclusion

In this case report, we present two pediatric
patients with two kinds of gene mutations who
received VNS treatment and experienced
different outcomes. Moreover, the brain network
properties of the two patients changed in
varying degrees after 6 months of VNS therapy.
Further prospective or retrospective studies
should be conducted to examine the correlation
between drug‐resistant epilepsy due to different
gene mutations and the efficacy of VNS and the
Journal of Neurorestoratology
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impact of VNS therapy on brain network.
[7]
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